

Synthesis of 3-aryl-8-oxo-5,6,7,8-tetrahydroindolizines *via* a palladium-catalyzed arylation and heteroarylation

Stéphanie Gracia, Clément Cazorla, Estelle Métay, Stéphane Pellet-Rostaing, and Marc Lemaire**

Supporting Information Index

Synthesis

1-H-pyrrole-1-butanoic acid (3)	S3
6,7-dihydroindolizin-8(5H)-one (4)	S3
3-phenyl-8-oxo-5,6,7,8-tetrahydroindolizine (5a)	S4
3-(4-cyanophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5b)	S4
3-(4-trifluoromethylphenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5c)	S5
3-(4-nitrophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5d)	S5
3-(4-acetylphenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5e)	S5
3-(4-methylbenzoyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5f)	S6
3-(2-nitrophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5g)	S6
3-(4-methoxyphenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5i)	S6
3-(3-acetylphenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5k)	S7
3-(3-chlorophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5l)	S7
3-(3-methoxyphenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5m)	S7
3-(3-toluy1)-8-oxo-5,6,7,8-tetrahydroindolizine (5n)	S8
3-(4-methoxy-2nitrophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5p)	S8
3-(3-quinoliny1)-8-oxo-5,6,7,8-tetrahydroindolizine (5r)	S8
3-(1-naphtyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5t)	S9
5,6,7,8-tetrahydroindolizine (10)	S9
3-phenyl-5,6,7,8-tetrahydroindolizine (11)	S10

NMR Spectra

1-H-pyrrole-1-butanoic acid (3)	S11
6,7-dihydroindolizin-8(5H)-one (4)	S12
3-phenyl-8-oxo-5,6,7,8-tetrahydroindolizine (5a)	S13/S14
3-(4-cyanophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5b)	S15
3-(4-trifluoromethylphenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5c)	S16/S17
3-(4-nitrophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5d)	S18
3-(4-acetylphenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5e)	S19
3-(4-methylbenzoyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5f)	S20/S21
3-(2-nitrophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5g)	S22
3-(4-methoxyphenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5i)	S23
3-(3-acetylphenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5k)	S24
3-(3-chlorophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5l)	S25/S26
3-(3-methoxyphenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5m)	S27
3-(3-toluy)l)-8-oxo-5,6,7,8-tetrahydroindolizine (5n)	S28/S29
3-(4-methoxy-2nitrophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5p)	S30
3-(3-quinoliny)l)-8-oxo-5,6,7,8-tetrahydroindolizine (5r)	S31
3-(1-naphtyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5t)	S32/33
5,6,7,8-tetrahydroindolizine (10)	S34
3-phenyl-5,6,7,8-tetrahydroindolizine (11)	S35

Experimental Section

Starting materials were obtained from commercial suppliers and used without further purification. 1-Methyl-2-pyrrolidone was distilled prior to use. Flash chromatographic purification was carried out on 230-400 mesh silica gel 60. NMR spectra were recorded on DRX 300 Brücker FT spectrometers. Abbreviation was used as: s (singlet), d (doublet), dd (divided doublet), t (triplet), q (quadruplet), quin (quintuplet), m (multiplet).

Synthesis of 1-H-pyrrole-1-butanoic acid (3): 4-Aminobutyric acid (10.0 g, 97.0 mmol), H₂O (150 mL), NaOAc (8.0 g, 97.5 mmol), AcOH (50 mL) and 1,2-dichloroethane (150 mL) were mixed and heated at 90 °C. 2,5-Dimethoxytetrahydrofuran (12.5 mL, 12.8 g, 97.2 mmol) was added and at 90 °C for 15 h. The reaction mixture was quenched with aqueous HCl 1N and extracted with CH₂Cl₂. The pH was adjusted to 10 with saturated aqueous solution of NHCO₃ and the organic phase was removed. The aqueous layer was made acidic with aqueous HCl solution and extracted with CH₂Cl₂. The organic phase was dried over Na₂SO₄ and concentrated to afford 14.5 g (98%) of the desired product as yellow oil. ¹H NMR (CDCl₃, 300 MHz): δ 2.18 (quin, 2H, *J* = 6.9 Hz), 2.42 (t, 2H, *J* = 6.9 Hz), 4.04 (t, 2H, *J* = 6.9 Hz), 6.29 (t, 2H, *J* = 2.1 Hz), 6.76 (t, 2H, *J* = 2.1 Hz), 11.62 (s, 1 H); ¹³C NMR (CDCl₃, 75 MHz): δ 26.9 (CH₂), 31.3 (CH₂), 48.8 (CH₂), 108.9 (CH), 121.1 (CH), 180.1 (C_q); HRMS[EI] calculated for C₈H₁₁NO₂: 153.0790 found: 153.0791.

Synthesis of 6,7-dihydroindolizin-8(5H)-one (4) : 4-(Pyrrol-1-yl)butanoic acid **3** (14.5 g, 94.8 mmol) was stirred in polyphosphoric acid (>84% phosphate as P₂O₅) (70 mL) at 30°C for 16 h. The reaction mixture was quenched with water (200 mL), and the resulting solution was extracted with CH₂Cl₂ (3 × 50 mL). The organic phases were combined, dried over Na₂SO₄, filtered and concentrated. Purification by column chromatography (silica gel, cyclohexane/ethyl acetate 8/2) afforded 12.9 g of 6,7-dihydroindolizin-8(5H)-one (12.9 g, 97%) as a colorless oil. ¹H NMR (CDCl₃, 300 MHz): δ 2.23 (m, 2 H), 2.53 (t, 2H, *J* = 6.2

Hz), 4.08 (t, 2H, J = 6.2 Hz), 6.21 (dd, 1H, J = 2.5, 4.1 Hz), 6.83 (t, 2H, J = 1.9 Hz), 6.97 (dd, 1H, J = 1.7, 4.1 Hz); ^{13}C NMR (CDCl_3 , 75 MHz): δ 23.9 (CH_2), 36.5 (CH_2), 45.5 (CH_2), 110.7 (CH), 114.3 (CH), 126.3 (CH), 187.7 (C_q); IR: 3110, 3099, 2960, 2950, 2924, 2888, 1647, 1525, 1482, 1388, 1338, 1325 cm^{-1} ; HRMS[EI] calculated for $\text{C}_8\text{H}_9\text{NO}$: 135.0684 found: 135.0684.

Representative procedure for arylation of compound (4): 8-oxo-5,6,7,8-tetrahydroindolizine **4** (1 g, 7.35 mmol), KOAc (1.44 g, 14.7 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (26 mg, 0.0367 mmol) and arylbromide (8.8 mmol) followed by freshly distilled NMP (4 mL) were added to a schlenk flask under argon atmosphere. The mixture was stirred at 100°C for 10 min. Then, water (23 μL , 1.3 mmol) was added to the solution. The reaction mixture was stirred at 100°C for the appropriate time then diluted with dichloromethane (30 mL), was washed with water (3x10 mL). The organic layer was dried (Na_2SO_4) and the solvent was removed under reduced pressure. Purification by column chromatography (silica gel, cyclohexane/ethyl acetate 8/2) afforded the desired compound **5 a-t**.

3-phenyl-8-oxo-5,6,7,8-tetrahydroindolizine (5a): 88%; white solid; Mp = 121-122°C; ^1H NMR (CDCl_3 , 300 MHz): δ 2.17 (m, 2H), 2.55 (t, 2H, J = 6.2 Hz), 4.04 (t, 2H, J = 6.2 Hz), 6.27 (d, 1H, J = 4.1 Hz), 7.04 (d, 1H, J = 4.1 Hz), 7.37 (m, 5 H); ^{13}C NMR (CDCl_3 , 75 MHz): δ 23.9 (CH_2), 36.3 (CH_2), 44.5 (CH_2), 111.9 (CH), 114.7 (CH), 122.4 (CH), 125.9 (2 CH), 129.2 (2 CH), 132.4 (C_q), 135.4 (C_q), 137.5 (C_q), 187.9 (CO); IR: 3056, 3029, 2946, 2880, 1646, 1532, 1508, 1454, 1384, 1333 cm^{-1} ; HRMS[EI] calculated for $\text{C}_{14}\text{H}_{13}\text{NO}$: 211.0997 found: 211.0998.

3-(4-cyanophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5b): 93%; yellow solid; Mp = 168-169°C; ^1H NMR (CDCl_3 , 300 MHz): δ 2.26 (m, 2H), 2.63 (t, 2H, J = 6.4 Hz), 4.14 (t, 2 H, J = 5.74 Hz), 6.42 (d, 1H, J = 4.1 Hz), 7.09 (t, 1H, J = 4.1 Hz), 7.55 (td, 2H, J = 1.7, 8.1Hz), 7.72 (td, 2H, J = 1.78, 8.28 Hz); ^{13}C NMR (CDCl_3 , 75 MHz): δ 23.9 (CH_2), 36.2

(CH₂), 44.7 (CH₂), 111.8 (C_q), 112.3 (CH), 114.8 (CH), 118.7 (C_q), 129.3 (2 CH), 132.7 (C_q), 132.8 (2 CH), 136.3 (C_q), 136.9 (C_q), 187.9 (CO); IR: 3058, 3032, 2962, 2936, 2227, 1657, 1637, 1604, 1512, 1464, 1337 cm⁻¹; HRMS[EI] calculated for C₁₅H₁₂N₂O: 236.0950 found: 236.0950.

3-(4-trifluoromethylphenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5c): 79%; yellow solid; Mp = 132-133°C; ¹H NMR (CDCl₃, 300 MHz): δ 2.27 (m, 2 H), 2.65 (t, 2H, *J* = 6.4 Hz), 4.14 (t, 2H, *J* = 5.83 Hz), 6.41 (d, 1H, *J* = 4.1 Hz), 7.12 (t, 1H, *J* = 4.1 Hz), 7.56 (d, 2H, *J* = 8.1 Hz), 7.71 (d, 2H, *J* = 8.1 Hz); ¹³C NMR (CDCl₃, 75MHz): δ 23.9 (CH₂), 36.2 (CH₂), 44.5 (CH₂), 111.9 (CH), 114.7 (CH), 124.2 (C_q, *J*¹C-F = 270.6 Hz), 125.9 (2 CH, *J*³C-F = 11.45 Hz), 129.2 (2 CH), 130.3 (C_q, *J*²C-F = 32.73 Hz), 132.3 (C_q), 135.4 (C_q, *J*⁵C-F = 2.18 Hz), 137.52 (C_q), 187.8 (CO); ¹⁹F NMR (CDCl₃, 122MHz): -63.3024; IR: 2956, 2885, 1654, 1615, 1515, 1317, 1126 cm⁻¹; HRMS[EI] calculated for C₁₅H₁₂F₃NO: 279.0871 found: 279.0871.

3-(4-nitrophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5d): 82%; orange solid; Mp = 184-185°C; ¹H NMR (CDCl₃, 300 MHz): δ 2.19 (m, 2 H), 2.51 (t, 2H, *J* = 6.4 Hz), 4.08 (t, 2H, *J* = 5.74 Hz), 6.34 (d, 1H, *J* = 4.1 Hz), 6.94 (t, 1H, *J* = 4.1 Hz), 7.51 (dd, 2H, *J* = 2.1, 6.9 Hz), 8.15 (dd, 2H, *J* = 1.9, 6.9 Hz); ¹³C NMR (CDCl₃, 75MHz): δ 23.9 (CH₂), 36.3 (CH₂), 44.8 (CH₂), 112.7 (CH), 114.9 (CH), 124.4 (2 CH), 129.4 (2 CH), 133.0 (C_q), 136.5 (C_q), 138.2 (C_q), 147.4 (C_q), 187.9 (CO); IR: 2968, 2927, 2869, 1660, 1596, 1506, 1330 cm⁻¹; HRMS[EI] calculated for C₁₄H₁₂N₂O: 256.0848 found: 256.0848.

3-(4-acetylphenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5e): 71%; yellow solid; Mp = 159-160°C; ¹H NMR (CDCl₃, 300MHz): δ 2.22 (m, 2H), 2.60 (m, 5H), 4.13 (t, 2H, *J* = 5.74 Hz), 6.39 (d, 1H, *J* = 4.1 Hz), 7.06 (t, 1H, *J* = 4.1 Hz), 7.51 (d, 2H, *J* = 8.4 Hz), 7.99 (d, 2H, *J* = 8.4 Hz); ¹³C NMR (CDCl₃, 75MHz): δ 23.8 (CH₂), 26.8 (CH₃), 36.2 (CH₂), 44.6 (CH₂), 111.9 (CH), 114.6 (CH), 128.8 (2CH), 128.9 (2CH), 132.4 (C_q), 136.2 (C_q), 136.4 (C_q), 137.8

(C_q), 187.8 (CO), 197.5 (CO); IR: 3095, 2959, 2921, 1676, 1651, 1604, 1508, 1465, 1336, 1248 cm⁻¹; HRMS[EI] calculated for C₁₆H₁₅NO₂: 253.1103 found: 253.1104.

3-(4-methylbenzoyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5f): 84%; yellow solid; Mp = 165-166°C; ¹H NMR (CDCl₃, 300MHz): δ 2.24 (m, 2H), 2.62 (t, 2H, *J* = 6.4 Hz), 3.92 (s, 3H), 4.14 (t, 2H, *J* = 5.74 Hz), 6.4 (d, 1H, *J* = 4.1 Hz), 7.09 (t, 1H, *J* = 4.1 Hz), 7.5 (d, 2H, *J* = 8.5 Hz), 8.08 (d, 2H, *J* = 8.5 Hz); ¹³C NMR (CDCl₃, 75MHz): δ 23.9 (CH₂), 36.3 (CH₂), 44.6 (CH₂), 53.5 (CH₃), 111.9 (CH), 114.7 (CH), 128.7 (2 CH), 129.7 (C_q), 130.2 (2 CH), 132.4 (C_q), 136.2 (C_q), 137.9 (C_q), 166.8 (CO), 187.8 (CO); IR: 3113, 2943, 2891, 1713, 1660, 1429, 1334, 1279, 1102 cm⁻¹; HRMS[EI] calculated for C₁₆H₁₅NO₃: 269.1052 found: 269.1052.

3-(2-nitrophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5g): 70%; yellow solid; Mp = 122-123°C; ¹H NMR (CDCl₃, 300MHz): δ 2.19 (m, 2H), 2.58 (t, 2H, *J* = 6.4 Hz), 3.77 (t, 2H, *J* = 5.84 Hz), 6.21 (d, 1H, *J* = 4.1 Hz), 7.04 (t, 1H, *J* = 4.1 Hz), 7.46 (dd, 1H, *J* = 1.5, 7.53 Hz), 7.60 (m, 2H), 8.05 (dd, 1H, *J* = 1.1, 7.9 Hz); ¹³C NMR (CDCl₃, 75MHz): δ 23.6 (CH₂), 36.2 (CH₂), 43.4 (CH₂), 111.4 (CH), 114.2 (CH), 124.8 (CH), 126.6 (C_q), 124.8 (CH), 126.6 (C_q), 130.4 (CH), 131.8 (C_q), 133.4 (CH), 133.5 (C_q), 149.4 (C_q), 187.7 (CO); IR: 2942, 2878, 1643, 1528, 1504, 1390, 1340 cm⁻¹; HRMS[EI] calculated for C₁₄H₁₂N₂O₃: 256.0848 found: 256.0847.

3-(4-methoxyphenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5i): 47%; yellow solid; Mp = 124-125°C; ¹H NMR (CDCl₃, 300MHz): δ 2.22 (m, 2H), 2.6 (t, 2H, *J* = 6.4 Hz), 3.84 (s, 3H), 4.08 (t, 2H, *J* = 5.74 Hz), 6.28 (d, 1H, *J* = 4.1 Hz), 6.97 (d, 2H, *J* = 8.8 Hz), 7.1 (d, 1H, *J* = 4.1 Hz), 7.35 (d, 2H, *J* = 8.85 Hz); ¹³C NMR (CDCl₃, 75MHz): δ 23.9 (CH₂), 36.3 (CH₂), 44.3 (CH₂), 55.6 (CH₃), 110.9 (CH), 114.4 (CH), 114.7 (C_q), 116.8 (C_q), 124.3 (2 CH), 130.3 (2 CH), 131.3 (C_q), 139.4 (C_q), 160.9 (C_q), 187.6 (CO); IR: 2960, 2936, 2891, 2830, 1640, 1609,

1518, 1458, 1341, 1238 cm^{-1} ; HRMS[EI] calculated for $\text{C}_{15}\text{H}_{15}\text{NO}_2$: 241.1103 found: 241.1103.

3-(3-acetylphenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5k): 84%; yellow solid; Mp = 164-165°C; ^1H NMR (CDCl_3 , 300MHz): δ 2.17 (m, 2H), 2.54 (m, 5H), 4.06 (t, 2H, J = 5.64 Hz), 6.31 (d, 1H, J = 4.1 Hz), 7.01 (d, 1H, J = 4.1 Hz), 7.48 (t, 1H, J = 7.62 Hz), 7.56 (dd, 1H, J = 1.5, 6.42 Hz), 7.87 (dd, 1H, J = 1.32, 7.44 Hz), 7.94 (d, 1H, J = 1.5 Hz); ^{13}C NMR (CDCl_3 , 75MHz): δ 23.8 (CH_2), 26.8 (CH_3), 36.2 (CH_2), 44.3 (CH_2), 111.5 (CH), 114.6 (CH), 128.2 (CH), 128.5 (CH), 129.3 (CH), 131.9 (C_q), 132.3 (C_q), 133.3 (CH), 137.7 (C_q), 138.0 (C_q), 187.7 (CO), 197.7 (CO); IR: 3062, 2960, 2873, 1667, 1649, 1499, 1339 cm^{-1} ; HRMS[EI] calculated for $\text{C}_{16}\text{H}_{15}\text{NO}_2$: 253.1103 found: 253.1102.

3-(3-chlorophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5l): 94%; yellow solid; Mp = 118-119°C; ^1H NMR (CDCl_3 , 300MHz): δ 2.26 (m, 2H), 2.64 (t, 2H, J = 6.3 Hz), 4.12 (t, 2H, J = 5.74 Hz), 6.36 (d, 1H, J = 4.1 Hz), 7.11 (d, 1H, J = 4.1 Hz), 7.33 (m, 4H); ^{13}C NMR (CDCl_3 , 75MHz): δ 23.9 (CH_2), 36.4 (CH_2), 44.5 (CH_2), 111.7 (CH), 114.8 (CH), 127.2 (CH), 128.6 (CH), 129.0 (CH), 130.3 (CH), 132.1 (C_q), 133.7 (C_q), 134.9 (C_q), 137.7 (C_q), 187.8 (CO); IR: 3061, 2977, 2932, 2845, 1639, 1599, 1500, 1456, 1429, 1384, 1344, 1333, 1089, 1074, 1038 cm^{-1} ; HRMS[EI] calculated for $\text{C}_{14}\text{H}_{12}\text{ClNO}$: 245.0607 found: 245.0607.

3-(3-methoxyphenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5m): 91%; yellow solid; Mp = 153-154°C; ^1H NMR (CDCl_3 , 300MHz): δ 2.24 (m, 2H), 2.63 (t, 2H, J = 6.4 Hz), 3.85 (s, 3H), 4.14 (dd, 2H, J = 5.82, 7.14 Hz), 6.36 (d, 1H, J = 4.1 Hz), 6.97 (m, 3H), 7.12 (d, 1H, J = 4.1 Hz), 7.36 (t, 1H, J = 7.89 Hz); ^{13}C NMR (CDCl_3 , 75MHz): δ 24.0 (CH_2), 36.4 (CH_2), 44.5 (CH_2), 55.7 (CH_3), 111.4 (CH), 113.9 (CH), 114.8 (CH), 115.0 (CH), 121.5 (CH), 130.1 (C_q), 131.8 (C_q), 133.2 (C_q), 139.3 (C_q), 160.0 (C_q), 187.8 (CO); IR: 3089, 2957, 2893, 2837, 1638, 1611, 1501, 1467, 1383, 1332, 1175, 1046 cm^{-1} ; HRMS[EI] calculated for $\text{C}_{15}\text{H}_{15}\text{NO}_2$: 241.1103 found: 241.1102.

3-(3-toluy1)-8-oxo-5,6,7,8-tetrahydroindolizine (5n): 49%; yellow solid; Mp = 140-141°C; ^1H NMR (CDCl_3 , 300MHz) : δ 2.19 (m, 2H), 2.39 (s, 3H), 2.58 (t, 2H, J = 6.4 Hz), 4.09 (dd, 2H, J = 5.85, 7.17 Hz), 6.30 (d, 1H, J = 4.1 Hz), 7.08 (d, 1H, J = 4.1 Hz), 7.24 (m, 4H) ; ^{13}C NMR (CDCl_3 , 75MHz) : δ 21.6 (CH_3), 23.8 (CH_2), 36.1 (CH_2), 44.2 (CH_2), 111.0 (CH), 114.5 (CH), 125.9 (CH), 128.7 (CH), 129.1 (CH), 129.6 (CH), 131.5 (C_q), 131.6 (C_q), 138.5 (C_q), 139.4 (C_q), 187.6 (CO); IR: 2992, 2977, 2934, 2865, 1637, 1608, 1532, 1499, 1468, 1385, 1343, 1332 cm^{-1} ; HRMS[EI] calculated for $\text{C}_{15}\text{H}_{15}\text{NO}$: 225.1154 found: 225.1155.

3-(4-methoxy-2nitrophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5p): 56%; orange solid; Mp = 123-124°C; ^1H NMR (CDCl_3 , 300MHz) : δ 2.21 (m, 2H), 2.60 (t, 2H, J = 6.4 Hz), 3.76 (t, 2H, J = 5.5 Hz), 3.93 (s, 3H), 6.19 (d, 1H, J = 3.8 Hz), 7.07 (d, 1H, J = 3.9 Hz), 7.20 (dd, 1H, J = 2.3, 8.5 Hz), 7.36 (d, 1H, J = 8.5 Hz), 7.57 (s, 1H) ; ^{13}C NMR (CDCl_3 , 75MHz) : δ 23.9 (CH_2), 36. 6 (CH_2), 43.5 (CH_2), 55.6 (CH_3), 101.1 (CH), 104.5 (CH), 109.9 (C_q), 111.8 (CH), 114.6 (CH), 131.5 (C_q), 132.5 (CH), 136.1 (C_q), 147.2 (C_q), 161.7 (C_q), 187.9 (CO); IR: 3121, 3063, 2961, 2830, 1651, 1536, 1512, 1468, 1444, 1340, 1305, 1288, 1234, 1032 cm^{-1} ; HRMS[EI] calculated for $\text{C}_{15}\text{H}_{14}\text{N}_2\text{O}_4$: 286.0954 found: 286.0954.

3-(3-quinolinyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5r): 78%; yellow solid; Mp = 190-191°C; ^1H NMR (CDCl_3 , 300MHz) : δ 2.19 (m, 2H), 2.53 (t, 2H, J = 6.4 Hz), 4.1 (t, 2H, J = 5.6 Hz), 6.39 (d, 1H, J = 4.1 Hz), 7.03 (d, 1H, J = 4.1 Hz), 7.48 (m, 1H), 7.64 (m, 1H), 7.76 (d, 1H, J = 8.1 Hz), 8.00 (d, 1H, J = 8.46 Hz), 8.09 (s, 1H), 8.88 (m, 1H); ^{13}C NMR (CDCl_3 , 75MHz) : δ 23.6 (CH_2), 36.0 (CH_2), 44.2 (CH_2), 111.9 (CH), 114.5 (CH), 124.8 (C_q), 127.4 (C_q), 127.5 (CH), 128.0 (CH), 129.3 (CH), 130.2 (CH), 132.2 (C_q), 135.0 (CH), 135.4 (C_q), 147.2 (C_q), 150.1 (CH), 187.6 (CO); IR: 3107, 2957, 2875, 1649, 1606, 1527, 1492, 1337 cm^{-1} ; HRMS[EI] calculated for $\text{C}_{17}\text{H}_{14}\text{N}_2\text{O}$: 262.1106 found: 262.1107.

3-(1-naphtyl)-8-oxo-5,6,7,8-tetrahydroindolizine (5t): 74%; grey solid; Mp = 155-156°C; ¹H NMR (CDCl₃, 300MHz) : δ 2.15 (t, 2H, *J* = 5.5 Hz), 2.61 (t, 2H, *J* = 5.8 Hz), 3.74 (t, 2H, *J* = 5.6 Hz), 6.39 (d, 1H, *J* = 3.9 Hz), 7.23 (d, 1H, *J* = 3.8 Hz), 7.55 (m, 5H), 7.92 (m, 2H); ¹³C NMR (CDCl₃, 75MHz) : δ 23.6 (CH₂), 36.0 (CH₂), 44.2 (CH₂), 111.9 (CH), 114.5 (CH), 124.8 (C_q), 127.4 (C_q), 127.5 (CH), 128.0 (CH), 129.3 (CH), 130.2 (CH), 132.2 (C_q), 135.0 (CH), 135.4 (C_q), 147.2 (C_q), 150.1 (CH), 187.6 (CO); IR: 3055, 2948, 2891, 2865, 1649, 1509, 1485, 1379, 1341 cm⁻¹; HRMS[EI] calculated for C₁₈H₁₅NO: 261.1154 found: 261.1154.


Preparation of 5,6,7,8-tetrahydroindolizine (10): To a cold (0°C) stirred suspension of aluminium chloride (1.47 g, 11.03 mmol) in dichloromethane (20 mL) was added *tert*-butylamine-borane (1.92 g, 22.06 mmol). The resulting mixture was allowed to stir at 0°C for 10 min. A solution of 6,7-dihydroindolizin-8(5H)-one (500 mg, 3.67 mmol) in dichloromethane (10 mL) was added. The resulting mixture was stirred at 0°C for 2 h. Cold dilute HCl (0.1 N, 20 mL) was added dropwise to the reaction mixture. The product was extracted with ethyl acetate. The combined organic extracts were washed with 0.1 N HCl twice and then with brine. Concentration of the organic extracts afforded an oil, which was purified by flash chromatography on silica gel (eluted with cyclohexane) to afford 447 mg (98%) of desired product as colourless oil. ¹H NMR (CDCl₃, 300MHz) : δ 1.91 (m, 2H), 2.00 (m, 2H), 2.85 (t, 2H, *J* = 6.2 Hz), 4.01 (t, 2H, *J* = 6.03 Hz), 5.9 (m, 1H), 6.19 (t, 1H, *J* = 3.0 Hz), 6.58 (1, 1H, *J* = 1.86 Hz); ¹³C NMR (CDCl₃, 75MHz) : δ 21.7 (CH₂), 23.5 (CH₂), 24.1 (CH₂), 44.5 (CH₂), 104.0 (CH), 107.6 (CH), 118.7 (CH), 129.3 (C_q); HRMS[EI] calculated for C₈H₁₁N: 121.0891 found: 121.0891.

Synthesis of 3-phenyl-5,6,7,8-tetrahydroindolizine (11): 70%; yellow oil; ¹H NMR (CDCl₃, 300 MHz): δ 1.90 (m, 4H), 2.89 (t, 2H, *J* = 6.1 Hz), 3.96 (t, 2H, *J* = 5.8 Hz), 5.95 (d, 1H, *J* = 3.6 Hz), 6.22 (d, 1H, *J* = 3.4 Hz), 7.28 (m, 1H), 7.37 (m, 4 H); ¹³C NMR (CDCl₃, 75

MHz): δ 24.1 (CH₂), 24.4 (CH₂), 30.0 (CH₂), 45.1 (CH₂), 105.0 (CH), 108.4 (CH), 126.6 (CH), 128.6 (2 CH), 128.9 (2 CH), 130.8 (C_q), 132.8 (C_q), 134.0 (C_q); IR: 3098, 3063, 3027, 2928, 1600, 1508, 1446, 1380, 1332, 1072, 1026 cm⁻¹; HRMS[CI] calculated for C₁₄H₁₅N: 198.1283 found: 198.1283.


solvent: CDCl₃

frequency: 300 MHz




solvent: CDCl₃

frequency: 300 MHz




4





solvent: CDCl₃

frequency: 300 MHz




5a






solvent: CDCl₃

frequency: 300 MHz




5b





solvent: CDCl₃

frequency: 300 MHz




5c






5c




solvent: CDCl₃

frequency: 300 MHz




5d




solvent: CDCl_3

frequency: 300 MHz




5e





solvent: CDCl₃

frequency: 300 MHz




5f






5f




solvent: CDCl_3

frequency: 300 MHz




5g




solvent: CDCl₃

frequency: 300 MHz




5i




solvent: CDCl_3

frequency: 300 MHz




5k





solvent: CDCl₃

frequency: 300 MHz




5l






solvent: CDCl₃

frequency: 300 MHz




5m





solvent: CDCl₃

frequency: 300 MHz




5n






5n




solvent: CDCl₃

frequency: 300 MHz




5p




solvent: CDCl₃

frequency: 300 MHz




5r





solvent: CDCl₃

frequency: 300 MHz




5t






solvent: CDCl_3

frequency: 300 MHz




10



solvent: CDCl₃

frequency: 300 MHz



11

